Mr. Hugh Rogers reports

BIONXT REPORTS UPDATE ON TARGETED CHEMOTHERAPY DRUG DELIVERY PLATFORM

Bionxt Solutions Inc. has made a significant advancement regarding its targeted chemotherapy delivery platform and provided a related definitive transaction update.

First announced July 8, 2025, the novel technology is a potential breakthrough targeted chemotherapy delivery platform designed to address a critical unmet need by localizing toxic chemotherapy drugs inside and around tumours while minimizing systemic exposure. The proprietary targeted drug delivery system employs a novel, dual-action mechanism that first concentrates potent chemotherapy drugs in close proximity to tumours and then rapidly neutralizes free drug molecules outside of the tumour location to protect healthy tissue. This targeted approach has demonstrated in vitro potential to enable a tenfold increase in therapeutic effect while maintaining the safety of healthy cells, significantly expanding the therapeutic window.

The research and development team has initiated the creation of a molecule data bank to feed prospective candidate molecules into the proprietary computational model to prioritize chemotherapy drugs for advanced research. The team has already identified a short list of dozens of high-priority targets. From this short list, the team is now focused on one drug that shows particular promise for proof of concept due to its pharmacokinetic properties. The prioritized candidate is currently used in both traditional chemotherapy and in other advanced targeted oncology treatments.

The company looks forward to announcing the next research and development steps and its patent strategy in the coming weeks and months. In addition, the company expects to sign a definitive agreement in the coming weeks and will report an update accordingly.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin-film), transdermal (skin patch), and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.